News

Patrys has assembled an international panel of critical care specialists to steer the development of RLS-2202, its injectable formulation of quetiapine for delirium in acute-care settings.

Hydrix has landed a multi-year contract with the National Heart Centre Singapore, giving the ASX-listed technology group a foothold in one of Asia's most prominent cardiac hospitals and a reference customer it hopes will open doors across the region.

Paradigm Biopharmaceuticals has appointed a new Chief Medical Officer as its osteoarthritis program moves from recruitment into a potential regulatory submission.

Tetratherix has reported early animal results for a cataract surgery gel that it says can be left in the eye without triggering the pressure spike, the most common early complication of the procedure.

Cambium Bio has secured a $10.85 million funding package for the pivotal Phase 3 trial of its dry eye treatment Elate Ocular.

AusBiotech has welcomed concessions to changes to the R&D Tax Incentive and Capital Gains Tax but remains concerned about the potential impact on emerging life sciences companies.

Noxopharm announced that its lead experimental therapy, SOF-SKN, will advance to an extension clinical study in patients with cutaneous lupus erythematosus, a painful, disfiguring skin condition with no targeted treatment currently available.

Six patients who had lived with binge eating disorder for as long as two decades sat down for two infusions of an experimental psychedelic drug. Three months later, all of them were still doing better. Half of them had not binged once.

Telix Pharmaceuticals has secured landmark approval from the United States Food and Drug Administration for Pixclara, making it the first FDA-sanctioned imaging agent for glioma, the most common form of brain cancer.

The controlled release covers Promarker D, a test that assesses a patient's risk of developing diabetic kidney disease up to four years before symptoms appear, and Promarker Eso, which helps rule out oesophageal cancer in patients suffering from chronic reflux.

The Sydney company has become the first in Australia to earn a manufacturing licence for viral vectors, a milestone it says strengthens the nation's capacity to make advanced gene and cell therapies at home rather than relying on overseas suppliers.

The grant, announced by Neurizon, will finance an Expanded Access Protocol for NUZ-001, the company's lead drug candidate for amyotrophic lateral sclerosis, commonly known as ALS or motor neurone disease.